- Home
- STTK vs PRT Comparison
STTK vs PRT Comparison
Compare STTK & PRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- PRT
- Stock Information
- Founded
- STTK 2016
- PRT 2017
- Country
- STTK United States
- PRT United States
- Employees
- STTK N/A
- PRT N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- PRT Oil & Gas Production
- Sector
- STTK Health Care
- PRT Energy
- Exchange
- STTK Nasdaq
- PRT Nasdaq
- Market Cap
- STTK 56.8M
- PRT 52.2M
- IPO Year
- STTK 2020
- PRT N/A
- Fundamental
- Price
- STTK $1.37
- PRT $4.37
- Analyst Decision
- STTK Hold
- PRT
- Analyst Count
- STTK 3
- PRT 0
- Target Price
- STTK $2.00
- PRT N/A
- AVG Volume (30 Days)
- STTK 131.9K
- PRT 58.4K
- Earning Date
- STTK 03-03-2025
- PRT 03-31-2025
- Dividend Yield
- STTK N/A
- PRT 9.96%
- EPS Growth
- STTK N/A
- PRT N/A
- EPS
- STTK N/A
- PRT 0.42
- Revenue
- STTK $6,435,000.00
- PRT $6,059,380.00
- Revenue This Year
- STTK $313.04
- PRT N/A
- Revenue Next Year
- STTK N/A
- PRT N/A
- P/E Ratio
- STTK N/A
- PRT $10.29
- Revenue Growth
- STTK 382.75
- PRT N/A
- 52 Week Low
- STTK $0.94
- PRT $3.26
- 52 Week High
- STTK $11.76
- PRT $4.64
- Technical
- Relative Strength Index (RSI)
- STTK 60.23
- PRT 61.17
- Support Level
- STTK $1.21
- PRT $4.21
- Resistance Level
- STTK $1.36
- PRT $4.37
- Average True Range (ATR)
- STTK 0.10
- PRT 0.15
- MACD
- STTK 0.01
- PRT -0.01
- Stochastic Oscillator
- STTK 90.00
- PRT 80.26
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive 80% of the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.